Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07527039 · ClinicalTrials.gov registry record · Phase 4
Pectoral Block in Breast Reduction for Pain Control
A Phase 4 study, sponsored by Carilion Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
NCT07527039: Recruiting Phase 4 study, sponsored by Carilion Clinic.
NCT07527039 is a Phase 4 study that is actively recruiting participants, run by Carilion Clinic. The registered enrollment target is 80 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07527039, a Phase 4 study, is actively recruiting participants, sponsored by Carilion Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
Study Summary
A reduction mammoplasty is a commonly performed procedure for patients with symptomatic macromastia. The procedure involves removing breast parenchyma for an overall reduction in breast size and to alleviate patient symptoms, such as back/neck pain, rashes in the inframammary fold, and bra strap indentation. It is well documented in the literature that this procedure has a statistically significant reduction in patient symptoms. Postoperatively, it has been within the norm to prescribe narcotics in order to alleviate post-procedural pain. Recently, however, the research realm has advocated a non-narcotic multimodal pain control (MMPC) approach to minimize narcotic usage. Narcotic use is associated with increased costs in the healthcare system due to reported heightened pain scores for extended duration, constipation, nausea, vomiting, opiate dependence among other factors associated with increased morbidity. The goal of this study is to determine if PECs II (pectoral block type II) block alone is non-inferior to the standard multimodal pain control with narcotics for postoperative pain reduction in breast reduction.
Primary Outcome
Participants are administered postoperative surveys on days 1, 3, and 7. These surveys assess type of analgesic medication usage and frequency. The primary purpose is to assess narcotic usage between the two groups to observe a reduction or elimination in narcotic usage in the control group
Interventions
- PROCEDURE Pectoral II Nerve Block
- DRUG Post Operative Pain Relievers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2028-05 |
| Phase | Phase 4 |
What NCT07527039 shows while recruiting
NCT07527039 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Pectoral II Nerve Block is the first listed.
NCT07527039 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07527039 about?
NCT07527039 is a clinical study titled "Pectoral Block in Breast Reduction for Pain Control". A reduction mammoplasty is a commonly performed procedure for patients with symptomatic macromastia. The procedure involves removing breast parenchyma for an overall reduction in breast size and to alleviate patient symptoms, such as back/neck pain, rashes in the inframammary fold, and bra strap ind...
What is the current status of trial NCT07527039?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2026-04-01. Estimated completion is 2028-05.
What interventions are being tested in trial NCT07527039?
The interventions under investigation include: Pectoral II Nerve Block (PROCEDURE), Post Operative Pain Relievers (DRUG).
Who is sponsoring clinical trial NCT07527039?
This trial is sponsored by Carilion Clinic, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07527039's enrollment target sits among peer trials
80 946th of 2000 higher than 1,021 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI